Efficacy and Survival of Systemic Psoriasis Treatments
Standard
Efficacy and Survival of Systemic Psoriasis Treatments : An Analysis of the Swiss Registry SDNTT. / Maul, Julia-Tatjana; Djamei, Vahid; Kolios, Antonios G A; Meier, Barbara; Czernielewski, Justine; Jungo, Pascal; Yawalkar, Nikhil; Mainetti, Carlo; Laffitte, Emmanuel; Spehr, Christina; Anliker, Mark; Streit, Markus; Augustin, Matthias; Rustenbach, Stephan; Conrad, Curdin; Hafner, Jürg; Boehncke, Wolf-Henning; Borradori, Luca; Gilliet, Michel; Itin, Peter; French, Lars E; Häusermann, Peter; Navarini, Alexander A.
In: DERMATOLOGY, Vol. 232, No. 6, 2016, p. 640-647.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy and Survival of Systemic Psoriasis Treatments
T2 - An Analysis of the Swiss Registry SDNTT
AU - Maul, Julia-Tatjana
AU - Djamei, Vahid
AU - Kolios, Antonios G A
AU - Meier, Barbara
AU - Czernielewski, Justine
AU - Jungo, Pascal
AU - Yawalkar, Nikhil
AU - Mainetti, Carlo
AU - Laffitte, Emmanuel
AU - Spehr, Christina
AU - Anliker, Mark
AU - Streit, Markus
AU - Augustin, Matthias
AU - Rustenbach, Stephan
AU - Conrad, Curdin
AU - Hafner, Jürg
AU - Boehncke, Wolf-Henning
AU - Borradori, Luca
AU - Gilliet, Michel
AU - Itin, Peter
AU - French, Lars E
AU - Häusermann, Peter
AU - Navarini, Alexander A
N1 - © 2017 S. Karger AG, Basel.
PY - 2016
Y1 - 2016
N2 - BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis.PATIENTS AND METHODS: Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms. Here, baseline data and follow-up data for 1 year of patients included from October 2011 until December 2014 were analyzed.RESULTS: Within 39 months, 323 patients from 7 tertiary dermatology centers in Switzerland were recruited in the SDNTT; 165 patients received biologics and 158 conventional systemic therapies. Patients treated with biologics had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; p ≤ 0.005, p ≤ 0.013, p ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, p ≤ 0.003) compared to patients starting a conventional systemic treatment. PASI reduction was satisfying in both treatment groups, with 60.6% of patients treated with biologics achieving PASI75 after 1 year compared to 54.2% of patients receiving conventional systemic drugs (nonsignificant). On average, the drug survival in patients receiving a biologic therapy was significantly longer than those receiving conventional systemic treatments (30.5 vs. 19.2 months, p ≤ 0.001).CONCLUSIONS: In the real-world setting of a prospective national therapy registry, the application of current therapeutic guidelines for patients with moderate to severe psoriasis resulted in a PASI reduction of approximately 70% within the first year of treatment, but current therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36% of patients, respectively, at 1 year, highlighting a gap in efficacy between selective clinical trials and the real-world setting.
AB - BACKGROUND: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis.PATIENTS AND METHODS: Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms. Here, baseline data and follow-up data for 1 year of patients included from October 2011 until December 2014 were analyzed.RESULTS: Within 39 months, 323 patients from 7 tertiary dermatology centers in Switzerland were recruited in the SDNTT; 165 patients received biologics and 158 conventional systemic therapies. Patients treated with biologics had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; p ≤ 0.005, p ≤ 0.013, p ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, p ≤ 0.003) compared to patients starting a conventional systemic treatment. PASI reduction was satisfying in both treatment groups, with 60.6% of patients treated with biologics achieving PASI75 after 1 year compared to 54.2% of patients receiving conventional systemic drugs (nonsignificant). On average, the drug survival in patients receiving a biologic therapy was significantly longer than those receiving conventional systemic treatments (30.5 vs. 19.2 months, p ≤ 0.001).CONCLUSIONS: In the real-world setting of a prospective national therapy registry, the application of current therapeutic guidelines for patients with moderate to severe psoriasis resulted in a PASI reduction of approximately 70% within the first year of treatment, but current therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36% of patients, respectively, at 1 year, highlighting a gap in efficacy between selective clinical trials and the real-world setting.
KW - Biological Products
KW - Humans
KW - Psoriasis
KW - Registries
KW - Switzerland
KW - Treatment Outcome
KW - Journal Article
U2 - 10.1159/000452740
DO - 10.1159/000452740
M3 - SCORING: Journal article
C2 - 28076860
VL - 232
SP - 640
EP - 647
JO - DERMATOLOGY
JF - DERMATOLOGY
SN - 1018-8665
IS - 6
ER -
